Insight, China's Pharmaceutical Industry

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Zhejiang Acea Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Fineline Cube Nov 5, 2025

Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...

Company Deals

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal

Fineline Cube Nov 5, 2025

Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...

Company Deals

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles

Fineline Cube Nov 4, 2025

Swiss‑listed pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) confirmed a strategic alliance with platform biotech...

Company Drug

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron

Fineline Cube Nov 4, 2025

Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious,...

Company

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes

Fineline Cube Nov 4, 2025

The Shanghai Pudong New Area Market Supervision Administration issued an administrative penalty against Green Valley...

Company Drug

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products

Fineline Cube Nov 4, 2025

China‑based CARsgen Therapeutics Holdings Limited (HKG: 2171) unveiled clinical data for two allogeneic CAR‑T candidates...

Policy / Regulatory

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption

Fineline Cube Nov 4, 2025

The Guangzhou Municipal Health Commission issued a comprehensive notice detailing twelve strategic measures aimed at...

Company Drug

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer

Fineline Cube Nov 4, 2025

China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China...

Company Drug

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors

Fineline Cube Nov 4, 2025

China‑based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA)...

Policy / Regulatory

NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale

Fineline Cube Nov 4, 2025

The National Healthcare Security Administration issued a comprehensive notice to strengthen the intelligent monitoring of...

Company Medical Device

Amoy Diagnostics Announce NMPA Approval of China’s First KRAS G12C Companion Diagnostic

Fineline Cube Nov 4, 2025

Amoy Diagnostics Co., Ltd. (“AmoyDx”) have secured approval from the China National Medical Products Administration...

Company Drug

GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa

Fineline Cube Nov 4, 2025

China‑based GenAns Biotechnology Co., Ltd. announced that its proprietary gene‑therapy drug GA001 injection received Fast‑Track...

Company Drug

Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting

Fineline Cube Nov 4, 2025

China‑based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines—olverembatinib (HQP1351), a first‑in‑China...

Company Deals

Sanyou Biopharmaceuticals and Liferiver Bio-Tech Forge Automation‑Driven Alliance to Accelerate Biologic Development

Fineline Cube Nov 4, 2025

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai Liferiver Bio-Tech Co., Ltd. (SHA: 688317) inked a...

Hospital

Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital

Fineline Cube Nov 4, 2025

Yangzi State‑Owned Investment Group (JSIG) and Singapore‑based Perennial Real Estate Holdings Limited (Perennial Group) signed...

Company Drug

Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina

Fineline Cube Nov 3, 2025

Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...

Company Deals Drug

TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration

Fineline Cube Nov 3, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced today that it has entered into a royalty‑bearing patent‑assignment...

Company Deals

Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy

Fineline Cube Nov 3, 2025

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework...

Company

AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges

Fineline Cube Nov 3, 2025

U.S. biopharma leader AbbVie Inc. (NYSE: ABBV) released its third‑quarter fiscal‑2025 results. Net revenues rose...

Insight, China's Pharmaceutical Industry

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors

NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale

Amoy Diagnostics Announce NMPA Approval of China’s First KRAS G12C Companion Diagnostic

GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa

Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting

Sanyou Biopharmaceuticals and Liferiver Bio-Tech Forge Automation‑Driven Alliance to Accelerate Biologic Development

Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital

Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina

TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration

Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy

AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges

You Missed

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis